Patent Law Weblog
recent posts
- Reasons for the PTAB’s Priority Determination in Broad’s Favor (Perhaps)
- Mexico Publishes Amendments to Intellectual Property Law
- PTAB (Again) Awards Priority of Invention to Broad in Interference No. 106,115
- Argentina Repeals Pharmaceutical Patent Examination Guidelines
- USPTO Moves to Protect Design Rights for Digital Innovations
about
Month: August 2007
-
August 23-24, 2007 – Current Issues in Complex IP Licensing: Business and Legal Factors for Licensing Transactions (Law Seminars International) – Seattle, WA August 24, 2007 – Managing Patent Prosecution and Litigation: New Regulations, Rules and Challenges, along with Practical Tips for Success (law Seminars International) – San Francisco, CA September 18-19, 2007 – Pharma/Biotech…
-
Law Seminars International (LSI) will be holding a conference entitled "Biotechnology: Business and Legal Developments" on September 27-28, 2007 in Seattle, WA. The conference will address legal and business issues facing the biotech industry, including funding approaches, licensing and collaboration trends, merger and acquisition developments, and evolving intellectual property and regulatory issues. In particular, the…
-
Law Seminars International (LSI) will be holding a conference entitled "Managing Patent Prosecution and Litigation: New Regulations, Rules and Challenges, along with Practical Tips for Success" on August 24, 2007 in San Francisco, CA. The conference will analyze the implications of on-going Patent Office and legislative changes and address strategic patent portfolio development and patent…
-
Law Seminars International (LSI) will be holding a conference entitled "Current Issues in Complex IP Licensing: Business and Legal Factors for Licensing Transactions" on August 23-24, 2007 in Seattle, WA. The conference will address business and legal factors that must be addressed to achieve a mutually beneficial licensing arrangement. In particular, the conference's speakers will…
-
Aventis Prevails over Impax in Riluzole Dispute By Robert Dailey — On remand from the Federal Circuit (see "Impax Labs., Inc. v. Aventis Pharm. Inc. (Fed. Cir. 2006)"), the District Court found that U.S. Pat. No. 5,527,814 is not anticipated by the prior art. Particularly, the Court found that the anticipating reference cited…
-
By Donald Zuhn — Further to our earlier report, the United States Patent and Trademark Office (USPTO) provided more details on Wednesday regarding the addition of the Japan Patent Office (JPO) to the Priority Document Exchange (PDX) program. In particular, the USPTO announced that for U.S. applications filed on or after July 28,…
-
By Christopher P. Singer — Genentech announced in an August 2, 2007 press release that the Hart-Scott-Rodino waiting period that applied to its acquisition of Tanox, Inc. has expired, and that the acquisition is now completed. The merger agreement, originally approved by Tanox shareholders on January 15, 2007, provides a cash payment of…
-
Denial of PI for Interim Patent Term Extension Affirmed By Sherri Oslick — In a nonprecedential opinion, the Federal Circuit affirmed the District Court of Delaware’s denial of Somerset’s request for preliminary injunction to compel the Director of the USPTO to grant an interim patent term extension. Somerset is the owner of U.S.…
-
By Christopher P. Singer — In an August 1, 2007 press release, Alnylam Pharmaceuticals, Inc. announced that the European Patent Office has issued a Rule 51(4) notification for European Patent 1 407 044 ("Tuschl II") which relates to RNA interference (RNAi) technology. In the same release, Alnylam also stated that the corresponding application…
-
By Jason Derry — Advanced Cell Technology, Inc. has announced that it will acquire Mytogen, Inc., which has completed a Phase I clinical trial relating to its Myoblast Program for treating heart failure. The Myoblast Program is a stem cell therapy approach to treating a patient having heart failure, in which autologous myoblasts…
Patent Docs 